Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0381-v1Release info

Latest

Research title

A biomarker study of a multicenter Phase II Trial of Nivolumab for Unresectable or Recurrent Thymic Carcinoma (NCCH1505)

Research overview

Aims
We explore biomarkers of nivolumab efficacy and safety in patients with unresectable or recurrent thymic carcinoma. In order to perform multifaceted analysis using blood and tumor tissue specimens, pathological evaluation, pharmacokinetic, and molecular imaging analysis, genomic analysis, and immunomonitoring were performed.
Methods
We analyze immune-related genes (SNV, indel analysis and function prediction, copy number mutation analysis, etc.) by Immuno-PGx panel with peripheral blood cell components.
Participants/materials
15 patients with thymic carcinoma participating in the NCCH1505 study
URL
N/A

Datasets

CartDataset IDType of dataAnalysis methodAccess criteriaDate published
JGAD000715NGS (Target Capture)
  • Targeted DNA sequencing
Controlled-access (Type I)2023-01-04

Data provider

Principal investigator
Hidehito Horinouchi
Affiliation
Department of Thoracic Oncology, Nantional Cancer Center Hospital

Research projects

No research projects.

Grants

NameTitleProject number
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED)
Study to Expand Indication of Nivolumab, an Anti-PD-1 Antibody, for Thymic Carcinoma and Thymoma
  • JP17ck0106161

Related publications

TitleDOIDataset ID
Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma
https://doi.org/10.3389/fonc.2022.966527 (opens in a new tab)

Controlled access users

No use of the controlled access data has been recorded.